Lexaria Bioscience Corp.LEXXEarnings & Financial Report
Lexaria Bioscience Corp is a global biotechnology firm specializing in innovative drug delivery technologies. Its patented DehydraTECH platform enhances the bioavailability, absorption speed, and efficacy of active pharmaceutical ingredients, cannabinoids, and nutraceutical compounds, serving healthcare, wellness, and pharmaceutical sectors primarily across North America and Europe.
LEXX Q1 FY2026 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-1.6M
Net Profit
$-1.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.07
Lexaria Bioscience Corp. Q1 FY2026 Financial Summary
Lexaria Bioscience Corp. reported revenue of $0 for Q1 FY2026, with a net profit of $-1.6M (up 41.0% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $1.6M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-1.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Lexaria Bioscience Corp. Annual Revenue by Year
Lexaria Bioscience Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $705.9K).
Lexaria Bioscience Corp. Quarterly Revenue & Net Profit History
Lexaria Bioscience Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $0 | — | $-1.6M | N/A |
| Q4 FY2025 | $174.0K | +107.1% | $-2.7M | -1549.3% |
| Q3 FY2025 | $174.0K | +107.1% | $-3.8M | -2177.6% |
| Q2 FY2025 | $174.0K | +20.0% | $-2.7M | -1559.3% |
| Q1 FY2025 | $183.9K | +21.6% | $-2.7M | -1470.0% |
| Q4 FY2024 | $84.0K | +173.3% | $-2.2M | -2600.9% |
| Q3 FY2024 | $84.0K | +8.1% | $-1.8M | -2121.1% |
| Q2 FY2024 | $145.0K | +624.1% | $-649.5K | -448.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145000 | $84000 | $84000 | $183923 | $174000 | $174000 | $174000 | $0 |
| YoY Growth | 624.1% | 8.1% | 173.3% | 21.6% | 20.0% | 107.1% | 107.1% | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.4M | $10.0M | $8.9M | $9.8M | $8.7M | $6.7M | $4.2M | $6.1M |
| Liabilities | $204203 | $271375 | $1.2M | $399718 | $1.9M | $1.6M | $1.6M | $1.5M |
| Equity | $6.5M | $10.1M | $8.0M | $9.8M | $7.1M | $5.6M | $3.0M | $4.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-619614 | $-1.3M | $-1.9M | $-2.7M | $-1.5M | $-3.6M | $-2.6M | $-984098 |